IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Mono Pharmacare IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Ahmedabad and caters to Pharmaceutical sector. Unistone Capital Private is the merchant banker of Mono Pharmacare IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 11th April 2023.
Mono Pharmacare IPO posted revenues of Rs 37.10 crores and PAT of Rs 1.23 crores in FY23 on annualised basis.Financial results of Mono Pharmacare IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Mono Pharmacare IPO PAT Margin is 2.24%, ROCE (Return on Capital Employed) is 25.40% as per latest financial. The below table shows Mono Pharmacare IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Mono Pharmacare IPO is Rs 49.47 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Mono Pharmacare IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Mono Pharmacare IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Mono Pharmacare IPO is ₹49.47 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Mono Pharmacare IPO has a Price-to-Earnings (PE) ratio of 40.00 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Mono Pharmacare IPO reported revenue of ₹37.10 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Mono Pharmacare IPO provide insights into sales growth, market demand, and business scalability.
Mono Pharmacare recorded an EBITDA of ₹ 1.56 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Mono Pharmacare Profit After Tax (PAT) is ₹0.73 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 32.63 Cr.
EBITDA Margin:
4.78
%
Net Worth: ₹ 10.84 Cr.
Market Capitalisation:
₹ 49.47 Cr.
P/E:
40.00 times
P/BV: 1.93 times
EV/EBITDA: 38.69 times
Mono Pharmacare operates in Pharmaceutical and Marketing Of Pharmaceutical Products. The Issue is listed on NSE EMERGE in Sep, 2023. Mono Pharmacare IPO size was 14.84 with Issue price of 28.00 .
Merchant Banker(s) of Mono Pharmacare IPO: Unistone Capital Private Limited
Mono Pharmacare IPO subscription was 13.42 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Mono Pharmacare IPO listed at a listing price of 30.45 against the offer price of 28.00.
The current market price of Mono Pharmacare is 24.35.
Why Us?
